Figure 5.
Effect of N/OFQ, UFP-101, and J-113397 on striatal DA release. Effects of N/OFQ (10 nmol), UFP-101 (30 nmol), and J-113397 (1 nmol) injection in the SNr (A) or J-113397 systemic administration (1-3 mg/kg, i.p.) (B) on spontaneous DA release in the DLS. A, Basal DA (in nanomolar) and AUC (in arbitrary units) values were: 1.52 ± 0.17, 7001 ± 112.8 (saline; n = 10),1.48 ± 0.16,5460 ± 374.4 (10 nmol of N/OFQ; n = 5), 2.13 ± 0.40, 9363 ± 252 (30 nmol of UFP-101; n = 5), 1.53 ± 0.12, and 9480 ± 173.5 (1 nmol of J-113397; n = 5). B, Basal DA (in nanomolar) and AUC (in arbitrary units) values were as follows: 1.48 ± 0.21, 7245 ± 195.6 (saline; n = 5), 1.25 ± 0.10, 7663 ± 219.9 (1 mg/kg J-113397; n = 4), 1.52 ± 0.32, and 11594 ± 956 (3 mg/kg J-113397; n = 4). Data are expressed as percentages ± SEM of basal pretreatment levels (calculated as the mean of the 2 samples before the treatment). **p < 0.01, significantly different from saline.